logo
Contractor Sentiment Generally Positive as the Worst of Price Pressures Ease, According to Office Fit Out Vendors Across Asia Pacific

Contractor Sentiment Generally Positive as the Worst of Price Pressures Ease, According to Office Fit Out Vendors Across Asia Pacific

Six Greater China cities are ranked in the top 20 most expensive office fit out markets in Asia Pacific
Hong Kong moves up four places to rank as fifth most expensive fit out market in Asia Pacific, remains most costly in Greater China
HONG KONG SAR - Media OutReach Newswire - 24 March 2025 - The cost to fit out an office in key locations across Asia Pacific has continued to rise, although at a slowing rate, according to findings from Cushman & Wakefield's Asia Pacific Fit Out Cost Guide 2025.
The global real estate service provider's annual report showed that fit out costs range from US$195 per square foot (psf) in Tokyo as the most expensive market, to US$58 psf in Jakarta as the least expensive. In Greater China markets, Hong Kong was at US$160, Beijing at US$100, and Shanghai at US$96.
Similarly to previous years and in line with expectations, Japanese cities were the most expensive markets while Southeast Asian cities were the most affordable locations for office fit outs. While there was some fluctuation at a market level and within local currencies, the ranking of most to least expensive fit out costs in US$ per square foot remained largely unchanged, though gaps have narrowed between some markets. Hong Kong was a notable market mover, moving up from ninth to fifth in the Asia Pacific listing, overtaking Auckland, Seoul, Sydney, and Melbourne, due to the strong US$ and consequently the HK$.
Report author Dr Dominic Brown said changes to local fit out costs were largely aligned with the economic outlook of each market and the related office leasing activity.
'As a region, Asia Pacific is one of the more expansionary, and we have seen more growth and slightly more positive sentiment about the market by contractors here than in other regions.
'Measured by both contractor sentiment and actual cost, it appears that the worst of the pricing pressure from recent years has resolved and prices for raw materials are on the way down while tight labour markets continue to drive some wage inflation.'
In local currency, North Asian cities including Tokyo, Seoul and Osaka saw the greatest fit out cost inflation of around 16%, followed by Australian cities, which averaged 11%. India recorded steady inflation of around 3% in most cities. In contrast, slower economic conditions in the Chinese mainland served to dampen contractor pricing change.
Top 10 most expensive locations for average fit out costs in Asia Pacific
RANK
CITY
AVERAGE COST
(US$ PSF)
1
Tokyo
195
2
Osaka
191
3
Nagoya
187
4
Canberra
172
5
Hong Kong
160
6
Auckland
158
7
Seoul
156
8
Sydney
153
9
Melbourne
150
10
Brisbane
146
Top six most expensive locations for fit out costs in Greater China
RANK
CITY
Basic Hybrid
(US$ PSF)
Collaborative Hybrid (US$ PSF)
(USD PSF)
Advanced Hybrid
(US$ PSF)
1
Hong Kong
96
160
257
2
Taipei
61
110
202
3
Beijing
68
100
150
4
Shanghai
70
96
164
5
Shenzhen
68
94
156
6
Guangzhou
65
92
156
In the Chinese mainland, against the dual backdrop of a slowdown in domestic economic growth and escalating international trade conflicts, tenants have adopted a more cautious approach in their office leasing decisions. Meanwhile, the construction market continues to undergo structural adjustments, and the Consumer Price Index (CPI) has remained at a low level for a long period of time. Office fit out costs in Chinese mainland Tier 1 cities have seen a degree of decline compared to the previous year, as reflected in the 2025 report.'
Read the full report here.
Hashtag: #Cushman&Wakefield
The issuer is solely responsible for the content of this announcement.
About Cushman & Wakefield
Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2024, the firm reported revenue of $9.4 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit www.cushmanwakefield.com.hk or follow us on LinkedIn ( https://www.linkedin.com/company/cushman-&-wakefield-greater-china).
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT)
Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT)

Yahoo

time24 minutes ago

  • Yahoo

Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT)

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the . On August 8, Leerink Partners analyst Mike Kratky reiterated a Buy rating on PROCEPT BioRobotics Corporation (NASDAQ:PRCT), keeping the associated price target at $83. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. He based the optimistic rating on the stability and growth of PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) performance, stating that the company reported a 4% sales beat in Q2. This growth was attributed to strong international momentum and higher average selling prices in the US. The analyst added that the company's full-year sales guidance was raised slightly despite a softer Q3, and the gross margin guidance was improved as well. This suggests a positive outlook for the rest of the year, according to the analyst. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage surgical robotics company that develops transformative solutions for urology. The company manufactures and sells the AquaBeam Robotic System, which is an image-guided, surgical robotic system used in minimally invasive urologic surgery. While we acknowledge the potential of PRCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

AleraCare and PURE Healthcare Announce Intent to Merge
AleraCare and PURE Healthcare Announce Intent to Merge

Yahoo

time24 minutes ago

  • Yahoo

AleraCare and PURE Healthcare Announce Intent to Merge

The combined company will create a leading ambulatory infusion platform with more than 75 outpatient locations across 14 states throughout the U.S. PHOENIX & TAYLORSVILLE, Utah, August 13, 2025--(BUSINESS WIRE)--AleraCare, a leading provider of infusion and specialty pharmacy services across the U.S., and PURE Healthcare, a leading national medical group that delivers healthcare services for individuals with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, Alzheimer's disease and other autoimmune conditions, today announced that the businesses have entered into a definitive merger agreement. Terms of the transaction were not disclosed. The proposed merger creates an unprecedented opportunity to provide high-quality patient care, improve clinical outcomes and enhance the availability of infusion services that lower the overall cost to the healthcare system overall. Founded in 2019, AleraCare's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. Administered at convenient, accessible, patient-first locations, AleraCare is focused on maintaining trusted-partner status with physicians, payors, drug distributors and pharmaceutical manufacturers. The company has rapidly expanded to over 30 ambulatory infusion centers across the country and is a provider-of-choice for infusion services to high-need and medically complex populations. Pure Healthcare, founded in 2018, is on a mission to transform the healthcare industry by making infusion therapy more affordable and accessible—while delivering a personalized, patient-centered experience. Pure specializes in treating chronic and autoimmune conditions such as Alzheimer's disease, multiple sclerosis, and rheumatoid arthritis, offering innovative, high-quality care tailored to individual needs. Its flagship offering, Pure Infusion Suites, has expanded to 43 locations across 14 states. These state-of-the-art suites prioritize patient comfort with private rooms, snacks, and entertainment, all while significantly lowering the cost of infusion services. Pure Healthcare also alleviates the administrative burden for referring providers by supporting patient authorizations and fostering strong partnerships with insurers, ensuring a seamless and efficient care journey from referral to treatment. The transaction is expected to close in the fourth quarter of 2025, and remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Holland & Knight is serving as legal counsel for AleraCare. Kunzler Bean & Adamson is serving as legal counsel and Cantor Fitzgerald is acting as financial advisor for PURE Healthcare. About AleraCare AleraCare is a leading provider of infusion treatments and pharmacy services for high-need and medically complex populations. The company's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. AleraCare provides care to patients in over 30 locations across six states throughout the U.S., including Arizona, California, Colorado, Idaho, New Mexico and Utah. For more information, please visit About PURE Healthcare Pure Healthcare, founded by BUILD Capital Partners in 2018, is a national medical group dedicated to reducing healthcare costs and improving outcomes for patients with complex chronic and autoimmune conditions like rheumatoid arthritis, Crohn's disease, multiple sclerosis, and Alzheimer's. As a market leader in infusion therapy, Pure Healthcare operates Pure Infusion Suites alongside specialty clinics in rheumatology and neurology, including Memory Treatment Centers and Montana Arthritis Centers. Through strategic payer partnerships, streamlined patient authorizations, and a commitment to personalized, high-quality care, Pure Healthcare delivers scalable value to patients, providers, and payers nationwide. Learn more at View source version on Contacts Media Contacts:AleraCare Mike GellerProfile Advisorsmgeller@ Pure Healthcare Andy Sortormarketing@

Top Stock Movers Now: Lennar, Gildan Activewear, CAVA Group, and More
Top Stock Movers Now: Lennar, Gildan Activewear, CAVA Group, and More

Yahoo

time24 minutes ago

  • Yahoo

Top Stock Movers Now: Lennar, Gildan Activewear, CAVA Group, and More

Key Takeaways U.S. equities edged higher at midday, with the S&P 500 and Nasdaq adding to their record closes, on optimism the Federal Reserve will lower interest rates next month. The hope of falling borrowing costs lifted shares of Lennar and rival home builders. CAVA Group's same-store sales came in well below expectations, sending shares of the Mediterranean-themed restaurant lower.U.S. equities edged higher at midday on continuing optimism the latest consumer inflation data will open the door to the Federal Reserve to cut interest rates next month. The S&P 500 and Nasdaq added to their record closes yesterday, and the Dow Jones Industrial Average was higher as well. Speculation that the Fed may make a large reduction in borrowing costs sent the 10-year Treasury yield lower and lifted shares of home builders Lennar (LEN), D.H. Horton (DHI), and PulteGroup (PHM). Shares of Gildan Activewear (GIL) jumped when the T-shirt manufacturer agreed to purchase undergarment maker Hanesbrands (HBI) for $2.2 billion, less than what was reported earlier. Hanesbrands shares gained as well. V2X (VVX) shares advanced on an upgrade from Bank of America, which said it was optimistic about the defense contractor's growth. CAVA Group (CAVA) shares tumbled when the Mediterranean-themed restaurant chain reported weaker-than-anticipated same-restaurant sales and reduced its guidance as consumers pulled back spending at its locations. Shares of CoreWeave (CRWV) tumbled after the provider of artificial intelligence computing posted a much larger-than-expected loss as expenses soared, and it warned it would continue to face higher costs to keep up with demand for its products. Circle Internet Group (CRCL) shares slid when the distributor of the USDC stablecoin announced a sale of 10 million Class A shares that includes 2 million from the company and 8 million from investors. Oil futures declined. Gold prices rose. The U.S. dollar lost ground to the euro, pound, and yen. Major cryptocurrencies were mixed. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store